<DOC>
	<DOCNO>NCT02381886</DOCNO>
	<brief_summary>A Phase I study IDH305 patient advanced malignancy harbor IDH1R132 mutation .</brief_summary>
	<brief_title>A Study IDH305 Patients With Advanced Malignancies That Harbor IDH1R132 Mutations</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Documented IDH1R132mutant tumor ECOG performance status â‰¤ 2 Patients receive prior treatment mutantspecific IDH1 inhibitor ( exception glioma patient ) Medical condition would prevent patient 's participation clinical study due safety concern compliance clinical study procedure presence clinically significant cardiac , respiratory , gastrointestinal , renal , hepatic neurological disease . Acute Promyelocytic Leukemia Women pregnant lactate Other protocoldefined Inclusion/Exclusion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>IDHR132 mutation</keyword>
	<keyword>IDH305</keyword>
	<keyword>IDH</keyword>
	<keyword>IDH1</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Acute</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Glioma</keyword>
	<keyword>Oligodendroglioma</keyword>
	<keyword>Astrocytoma</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>